NeoGenomics, Inc. (NEO) Financials
NEO Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.7 billion | 739.7 million |
2023-09-30 | 1.7 billion | 730.8 million |
2023-06-30 | 1.7 billion | 738.9 million |
2023-03-31 | 1.7 billion | 734.7 million |
NEO Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 10.7 million | 7.0 million |
2023-09-30 | -9.8 million | 7.2 million |
2023-06-30 | -9.0 million | 5.7 million |
2023-03-31 | -22.6 million | 4.8 million |
NEO Net Income
No data available :(
NEO Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 415.2 million | - | 73.5 million |
2023-09-30 | 402.3 million | - | 68.2 million |
2023-06-30 | 409.3 million | 536.8 million | 72.8 million |
2023-03-31 | 417.9 million | 536.0 million | 74.3 million |
NEO Shares Outstanding
NEO Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 7.1 million | 7.1 million | 59.8 million | 18.1 million |
2023-09-30 | 4.3 million | 5.3 million | 61.5 million | 17.6 million |
2023-06-30 | 7.5 million | 7.5 million | 60.3 million | 18.9 million |
2023-03-31 | 9.9 million | 7.4 million | 61.5 million | 16.3 million |
NEO Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 155.6 million | 88.0 million |
2023-09-30 | 152.0 million | 89.6 million |
2023-06-30 | 146.9 million | 87.0 million |
2023-03-31 | 137.2 million | 82.4 million |
NEO
Price: $14.72
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.70 USD
P/E Ratio: -18.65
Exchange: NCM
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 437800
Ebitda: 2.2 millionMarket Capitalization: 1.9 billion